Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 13 | 2024 | 142 | 2.360 |
Why?
|
| Positron-Emission Tomography | 14 | 2024 | 337 | 1.700 |
Why?
|
| Lung Neoplasms | 8 | 2024 | 2362 | 0.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 1123 | 0.760 |
Why?
|
| Radiopharmaceuticals | 6 | 2020 | 195 | 0.730 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 265 | 0.480 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 27 | 0.400 |
Why?
|
| Cysts | 2 | 2010 | 106 | 0.400 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2010 | 139 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 152 | 0.370 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2024 | 97 | 0.370 |
Why?
|
| Duodenal Diseases | 1 | 2010 | 23 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2015 | 2666 | 0.350 |
Why?
|
| Multimodal Imaging | 3 | 2015 | 111 | 0.320 |
Why?
|
| Whole Body Imaging | 4 | 2015 | 41 | 0.280 |
Why?
|
| Technetium | 2 | 2022 | 29 | 0.270 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 1254 | 0.270 |
Why?
|
| Tumor Burden | 6 | 2023 | 305 | 0.250 |
Why?
|
| Prognosis | 5 | 2024 | 3777 | 0.250 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 10 | 0.240 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 25 | 0.240 |
Why?
|
| Radionuclide Imaging | 4 | 2018 | 222 | 0.240 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 25 | 0.240 |
Why?
|
| Aged | 13 | 2024 | 19124 | 0.230 |
Why?
|
| Retrospective Studies | 9 | 2024 | 9097 | 0.230 |
Why?
|
| Subtraction Technique | 3 | 2011 | 130 | 0.230 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 67 | 0.230 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 123 | 0.230 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6761 | 0.210 |
Why?
|
| Neuroendocrine Tumors | 1 | 2024 | 122 | 0.200 |
Why?
|
| Erythrocytes | 1 | 2003 | 254 | 0.200 |
Why?
|
| Middle Aged | 13 | 2024 | 25971 | 0.200 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 320 | 0.200 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 749 | 0.200 |
Why?
|
| Female | 19 | 2024 | 46328 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2024 | 287 | 0.190 |
Why?
|
| Male | 19 | 2024 | 42438 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 665 | 0.180 |
Why?
|
| Humans | 29 | 2024 | 89500 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 237 | 0.180 |
Why?
|
| Sarcoidosis | 1 | 2020 | 72 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 688 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 124 | 0.170 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 164 | 0.170 |
Why?
|
| Image Enhancement | 3 | 2014 | 565 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 682 | 0.160 |
Why?
|
| Bone and Bones | 3 | 2011 | 271 | 0.150 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 21 | 0.140 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2016 | 36 | 0.140 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2011 | 332 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2011 | 471 | 0.130 |
Why?
|
| Mutation | 2 | 2024 | 4158 | 0.130 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2016 | 76 | 0.130 |
Why?
|
| Cystic Duct | 1 | 2014 | 5 | 0.120 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2014 | 12 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1172 | 0.120 |
Why?
|
| Gallbladder | 1 | 2014 | 31 | 0.120 |
Why?
|
| Cholecystitis, Acute | 1 | 2014 | 8 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2018 | 400 | 0.120 |
Why?
|
| Adult | 9 | 2024 | 26659 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1605 | 0.110 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 256 | 0.110 |
Why?
|
| Aspartic Acid | 1 | 2013 | 64 | 0.110 |
Why?
|
| Prealbumin | 2 | 2022 | 34 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 162 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 151 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 1727 | 0.100 |
Why?
|
| False Negative Reactions | 1 | 2010 | 63 | 0.090 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 327 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 192 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 333 | 0.080 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 69 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2012 | 287 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 366 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 523 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2010 | 320 | 0.080 |
Why?
|
| Echo-Planar Imaging | 1 | 2007 | 52 | 0.070 |
Why?
|
| Remission Induction | 1 | 2009 | 740 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 785 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2007 | 187 | 0.070 |
Why?
|
| Young Adult | 3 | 2018 | 6354 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 1997 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 219 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1535 | 0.060 |
Why?
|
| Octreotide | 1 | 2024 | 26 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2013 | 1064 | 0.060 |
Why?
|
| Fibrin | 1 | 2024 | 86 | 0.060 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 39 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2024 | 114 | 0.060 |
Why?
|
| Vascular Calcification | 1 | 2024 | 51 | 0.050 |
Why?
|
| Digestive System | 1 | 2003 | 42 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2762 | 0.050 |
Why?
|
| Inflammation | 1 | 2009 | 975 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 9 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.050 |
Why?
|
| Device Removal | 1 | 2024 | 168 | 0.050 |
Why?
|
| Angiography | 1 | 2003 | 208 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2323 | 0.050 |
Why?
|
| Biomarkers | 2 | 2022 | 1767 | 0.050 |
Why?
|
| Adolescent | 2 | 2018 | 9289 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 1245 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 43 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2024 | 229 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 51 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 8200 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 1886 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2014 | 4305 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2303 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 469 | 0.040 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2018 | 20 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 144 | 0.040 |
Why?
|
| Neoplasms | 1 | 2012 | 3052 | 0.040 |
Why?
|
| Observer Variation | 2 | 2010 | 612 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1353 | 0.040 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 32 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2016 | 88 | 0.030 |
Why?
|
| Calcium Channels | 1 | 2016 | 182 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1221 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 777 | 0.030 |
Why?
|
| Everolimus | 1 | 2013 | 35 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 849 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 315 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1860 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3173 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 3753 | 0.020 |
Why?
|
| Algorithms | 2 | 2011 | 1894 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 401 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 114 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1082 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2011 | 261 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2876 | 0.020 |
Why?
|
| Pineal Gland | 1 | 2007 | 15 | 0.020 |
Why?
|
| Texas | 1 | 2007 | 116 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2007 | 57 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7210 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 661 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2006 | 223 | 0.020 |
Why?
|
| Automation | 1 | 2006 | 111 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3658 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 5330 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2015 | 0.010 |
Why?
|
| Software | 1 | 2006 | 666 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3462 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1270 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2292 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5518 | 0.010 |
Why?
|